{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002072","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.340681+00:00","generated_at":"2026-06-20T18:02:03.259169+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiniksa reports preliminary ARCALYST revenue of $122.5M for FY2022; cash $190.4M","bullets":["ARCALYST net revenue Q4 2022 $39.9M, full-year $122.5M (unaudited).","Year-end 2022 cash, equivalents and ST investments $190.4M, funding into at least 2025.","Greater than 800 prescribers for recurrent pericarditis; 22% have prescribed for 2+ patients.","Payer approval rate >90%; approx 45% of patients who discontinued ARCALYST restarted therapy.","KPL-404 Phase 2 RA trial: 2 of 3 cohorts enrolled; proof-of-concept data expected 1H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002072","json":"https://secwatch.observer/filing/0001104659-23-002072.json","markdown":"https://secwatch.observer/filing/0001104659-23-002072.md","text":"https://secwatch.observer/filing/0001104659-23-002072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/tm232503d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:02:03.259169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47556bd5ea93bf81326b80938a5e6724bcb4b7fd","claim":"Kiniksa Pharmaceuticals International, plc reported the fourth quarter of 2022 results: revenue $39.9 million.","evidence_excerpt":"ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$39.9 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ce870a9e46100941e55bbe84e19f6e8e6f548779","claim":"Kiniksa Pharmaceuticals International, plc reported the full year 2022 results: revenue $122.5 million.","evidence_excerpt":"ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Revenue","value":"$122.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}